Huanyu (Harris) Tang

We are glad to have Loya Hirom, Assistant Vice President - Marketing, Oncquest Laboratories Ltd. as a key speaker for #ClinicalTrials Summit 2024 https://lnkd.in/gaFcSFXg For our upcoming conferences visit : https://lnkd.in/gjQY86dn Fen Castro #VIct #clinicalresearch #clinicaloperations #clinicaldevelopment #ClinicalResearchNews  #cro #qualitycontrol #qualityassurance #RegulatoryAffairs #RegulatoryWriting #pharmacovigilance #medicalaffairs #patientsafety #biosimilars #patientsafety #pharmaceuticalmanufacturing #pharmaceuticals #pharmaceuticalindustry #pharmanews #healthcare #medicines #lifesciences #biotech #mumbai 

6

【Interview with Jing Zhang, CFO of 3D Medicines: Achieve Profitablity with Market Essential Demand Product Portfolio】 🚀 With the distinction of owning the world’s only subcutaneous PD-L1 injection product, 3D Medicines has maintained a gross profit margin of over 90% for years, laying a strong foundation for commercialization. However, the timeline for reaching breakeven remains a key concern for investors. 📢 Futu I&E proudly had an in-depth conversation with Jing Zhang, CFO of 3D Medicines, discussing financial performance, product R&D, and international strategy. 🔑 We’ve distilled some core insights from this conversation to share with you: 🌟 The way to maintain consistently high gross profit margins 🌟 Perspective on international market expansion 🌟 Process of managing pharmaceutical R&D effectively 👉 Please click the link to read the full article: https://lnkd.in/gyWGeSsF #Futu #Futuie #Pharmaceuticals #Innovation #Commercialization #GlobalStrategy #Biotech

2

Watch On Demand https://buff.ly/4b95z7A Speakers John Liu, Head of Pharmacology, and Lin Teng, VP of Integrated Biology, combine 30+ years experience to share insights on recent drug discovery and development industry trends towards the improved treatment of metabolic dysfunction-associated steatotic liver disease (#MASLD), metabolic-associated fatty liver disease (#MAFLD), non-alcoholic fatty liver disease (#NAFLD), non-alcoholic steatohepatitis (#NASH), metabolic dysfunction-associated steatohepatitis (#MASH) and related disease.

15

Discover the intricate dynamics behind #Korean #oncologists' preference for originator #biologics over #biosimilars, despite their comparable efficacy and safety profiles. #Biosimilars #Oncology #Healthcare #InviMedsHealth #invimeds #onco #oncologist #korea #meds #medicine #innovatordrug #drug https://bit.ly/3wxZ1Az

6

Biosimilars Weekly Recap: #5: HLX22, an anti-HER2 antibody, to HLX02 biosimilar and XELOX chemotherapy extended PFS in patients with untreated HER2-positive advanced gastric cancer.  #4: Financial incentives introduced by Japan's 2022 health policy resulted in increased use of oncology biosimilars. #3: Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered. #2: The European Commission grants marketing authorization to 2 aflibercept biosimilars; Biosimilars Canada launches new campaign to provide sustainable solutions to employers; Celltrion shares positive data for 2 biosimilars. #1: Dr Niazi's latest article proposes the creation of a new association with rational scientific agenda. To read all of these articles: https://lnkd.in/gBGSZeqF

4

First Patient Enrolled in #Taiwan for Phase 2 HARMONIC™ Trial! 🚀 We’re thrilled to announce the first patient enrollment in Taiwan for our Phase 2 HARMONIC™ clinical trial evaluating LP-300 in never-smoker NSCLC patients. This milestone highlights our commitment to delivering targeted therapies to underserved populations. Key Highlights: 🔬 Over 50% of lung cancer cases in Taiwan occur in never-smokers.   🔬 LP-300 focuses on never-smoker #NSCLC, a unique disease entity requiring precision therapy.   🔬 This follows the encouraging preliminary results of 86% clinical benefit rate and 43% objective response rate among the first seven patients. 🔬 The trial is actively enrolling in multiple sites in the U.S., Japan, and Taiwan. We’re advancing progress with the goal of improving outcomes for never-smoker NSCLC patients worldwide. Stay tuned for updates! Read the full release: https://bit.ly/4g3Nme1 Learn more about the trial: www.harmonictrial.com

19

1 条评论

The APAC region is experiencing significant growth in clinical trials, but sourcing equipment presents unique challenges. In this latest article, We discuss: 🔹 Complex import/export regulations 🔹 Local sourcing limitations 🔹 Country-specific hurdles in China, India, Indonesia, and Vietnam 🔹 Cultural differences in equipment use 🔹 Import licenses and IOR requirements Understanding and addressing these issues is crucial for successful clinical trials in APAC. Read more about overcoming these challenges in the full article. 👉 https://lnkd.in/e3HVc2ci #ClinicalTrials #APAC #MedicalResearch #EquipmentSourcing

15

🚀Exciting news -  Lantern Pharma Inc. (Nasdaq: LTRN) announced that the first patient has been dosed in Japan for the Phase 2 HARMONIC™ clinical trial for LP-300 in never-smoker patients with non-small cell lung cancer(#NSCLC). 📍Non-small cell lung cancer (NSCLC) in never smokers occurs at rates 2 to 3 times higher in East Asian countries versus the US and Europe. 📍Ten clinical trial sites across Japan and Taiwan are actively screening patients, with additional sites expected to also begin patient enrollment in the coming months. 📍U.S. clinical sites continue to actively screen and dose patients in both the LP-300 combination arm and the standard-of-care control arm of the Harmonic™ trial. This marks an important milestone, driving the next phase of enrollment of the Harmonic trial™ - We’re encouraged by the strong support from clinical partners across Asia in advancing this unique trial to improve survival outcomes for never-smokers with lung cancer who have relapsed from TKI-based treatments! Read the full release: https://bit.ly/3UVasv5 Learn more about the trial: harmonictrial.com Clinicaltrial.gov (NCT05456256): https://lnkd.in/eKHWFphD

45

2 条评论

What’s APAC’s Recipe of Success in Clinical Trials Market? Asia-Pacific (APAC) is emerging as one of the most promising and resilient markets for clinical trials. According to a report by Clinical Trials Arena, between 2017 and 2022, the region posted growth in clinical trials of around 10 per cent, outstripping growth in other major regions including the US, Europe and the rest of the world (RoW). Asia’s growth far exceeded the overall average figure of 5.3 per cent per year. As of 2023, the number of trials reached 14,346 in APAC. Click here to read: https://lnkd.in/gyNt3QA9 Gowri Prasad Gutti Megan Morrison Suhail Ali Bryan C. Spielman Mahesh Bhalgat Danny Soon Ding Ming, PhD Manbeena Chawla Ph.D. #clinicalresearch #clinicaltrials

13

In Japan, the In-Country Clinical Caretaker (#ICCC) is a crucial role for foreign sponsors conducting clinical trials. Under Japanese Good Clinical Practices (JGCP) regulations, an ICCC is designated by the foreign sponsor to represent them during the clinical trial process. This role involves managing regulatory interactions with Pharmaceuticals and Medical Devices Agency (PMDA), safety reporting, and ensuring compliance with Japanese regulations.   #Micron strongly recommends for foreign sponsors who wish to penetrate the Japanese market to check below site for more information for ICCC. https://lnkd.in/g6bGmWrh   Micron can hear and support your needs from consultations with the PMDA on development strategies. We ensure that your trials meet Japan's high standards and regulatory requirements. For more information on ICCC's services, please visit our website. https://lnkd.in/g32_t_bg #Micron,#ICCC,#ImagingCRO,#clinicalresearch,#clinicalstudies,#clinicaltrials,#CRO, #ACROSSGlobal,#medicalimaging,#centralimaging,#imagingforclinicaltrials,#drugdevelopment

21

Collaboration on Flow Cytometry-Based Companion Diagnostics to Advance Personalized Health Care.  www.bd.com BD and Quest Diagnostics, a leader in diagnostic information services, announced a global collaboration agreement to develop, manufacture and commercialize flow cytometry-based companion diagnostics (CDx) intended to help select the best treatment for patients with cancer and other diseases. Together, BD and Quest will aim to provide the pharmaceutical industry with an end-to-end solution for CDx development. The joint offerings will range from exploratory panel development to the manufacturing and distribution of FDA-approved diagnostic kits. Using companion diagnostics to help select a first-line therapy for cancer patients can be critical to ensuring the best outcomes and cost savings. Today's companion diagnostic tests commonly involve technologies such as immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), next-genera

1

SDBN Feed: Roche to buy cell therapy developer Poseida for $1B https://lnkd.in/gkxV-Gk9 Swiss pharmaceutical giant Roche is spending around $1 billion to acquire a San Diego-based biotechnology company that’s trying to treat certain cancers and rare diseases with a slate of cell therapies and genetic medicines. The [...]

77

The Asia-Pacific region is witnessing a surge in #cellandgenetherapy studies, driven by patient demand and innovation. In China, the high incidence of solid tumors is accelerating the need for advanced therapies. Increased government support and investments are propelling #CGT trials forward. This growth presents significant opportunities and challenges for #drugdevelopers. Success in this competitive field requires expertise in clinical trial execution, navigating regulations and effective patient recruitment strategies. Learn more from our recent blog. ⬇️

41

1 条评论

Digital transformation (#DX) is revolutionizing the way we approach drug development and can play a key role in accelerating research. Yoshitsugu Shitaka, Astellas’ Chief Scientific Officer, and Nick Eshkenazi, Chief Digital & Transformation Officer, recently joined Research teams at our Tsukuba Research Center to discuss just that. At Astellas, we are harnessing the power of digital technologies to optimize small molecule compounds. By leveraging #AI and #robotics with the expertise of our researchers, we’ve dramatically reduced the time to identify a drug candidate compound by about 70% at maximum. And that is just one example. We are leveraging digital technology in various drug research areas, including biologics, gene therapy, and cell therapy. By making agile, informed decisions, we are committed to advancing drug research and delivering cutting-edge technologies to patients faster than ever before. Read more about our efforts of DX in research: https://lnkd.in/gbcZn6FB #DigitalTransformation #AI #robotics

249

3 条评论